silent voice survey a survey of prostate cancer patients in europe overview of results

Silent Voice Survey

A survey of prostate cancer patients in Europe

OVERVIEW OF RESULTS

Patient demographics

3

GfK HealthCare

Number of patients and age

Total

Country

France Germany Italy Spain Poland

Total number of patients 252 50 50 50 50 52

Age of patients TotalCountry

France Germany Italy Spain Poland

16-45 years 0% 2% 0% 0% 0% 0%

46-55 years 6% 8% 12% 4% 4% 4%

56-65 years 30% 34% 32% 38% 22% 25%

Over 65 years 63% 54% 56% 58% 74% 71%

Not stated 0% 2% 0% 0% 0% 0%

4

GfK HealthCare

Healthcare professional most involved in patient treatment and management following diagnosis

Total

Country

Healthcare professional France Germany Italy Spain Poland

The Urologist 67% 86% 66% 72% 40% 73%

The Oncologist 23% 8% 20% 14% 48% 25%

Your GP/Primary Care Physician

4% 2% 4% 8% 2% 2%

The Radiologist 2% 2% 4% 0% 4% 0%

The Radiotherapist 2% 0% 2% 6% 0% 0%

None of the above 1% 0% 4% 0% 0% 0%

Don't know 2% 2% 0% 0% 6% 0%

5

GfK HealthCare

Treatment course undertaken following diagnosis

Total

Country

Treatment course(s) France Germany Italy Spain Poland

Surgery 47% 58% 60% 44% 24% 50%

Hormone therapy 39% 26% 30% 70% 30% 40%

Radiotherapy37% 28% 40% 36% 52% 29%

Chemotherapy 9% 6% 18% 2% 18% 0%

Pharmacological treatment / tablets 6% 2% 4% 0% 8% 13%

Monitoring phase / waiting for a treatment decision

1% 4% 0% 0% 0% 2%

Infusions (unspec) 1% 0% 2% 0% 0% 2%

Injections (unspec) 0% 0% 0% 0% 2% 0%

Don't know 1% 0% 2% 0% 2% 0%

How are prostate cancer patients accessing

information about their condition?

7

GfK HealthCare

Did patients receive information about prostate cancer at diagnosis?

68%

32%

1%

19%

80%

34%

66%

2%

12%

86%

2%

8%

90%

2%

10%

88%

Yes

No

Don't know Total France Germany Italy Spain Poland

Base: All respondents (Total=252/France=50/Germany=50/Italy=50/Spain=50/Poland

=52)

JUNE 2009MAIN SURVEY

Q: When you were first diagnosed with prostate cancer were you given any information concerning this condition?

8

GfK HealthCare

How informative was the information patients were given about prostate cancer?

1%1%8%

32%

57%

6%3%

9%

21%

61%

21%

38%

41%

2%

40%

58%

2%2%4%

29%

62%

2%

9%

30%

59%

(4) - Veryinformative

3 2 1 - Not at allinformative

Don't know

Total France Germany Italy Spain Poland

Base: All who were given any information concerning prostate cancer when first diagnosed (Total=201/France=33/Germany=34/Italy=43/Spain=45/Poland=46)


Q: On a scale of 1 to 4, please rate the information you were given, upon being initially diagnosed with prostate cancer, for each of the following aspects? - Explanation of your condition

9

GfK HealthCare

How informative was the information patients were given about the likely outcome of their diagnosis?

18%

47%

24%

12%

56%

33%

7%4%

54%

35%

7%4% 1%

5%

11%

38%

44%

6%9%

9%

18%

58%

14%

53%

33%



Don't know




Q: On a scale of 1 to 4, where 1 is 'Not at all informative' and 4 is 'very informative', please rate the information you were given, upon being initially diagnosed with prostate cancer, for each of the following aspects?- Explanation of the likely outcome

10

GfK HealthCare

How informative was the information patients were given about their treatment options?

6%9%

34%

50%

6%6%

21%

67%

12%15%

41%

32%

2%

9%

42%

47%

7%

2%

31%

60%

2%4%

13%

35%

46%



Don't know




Q: On a scale of 1 to 4, where 1 is 'Not at all informative' and 4 is 'very informative', please rate the information you were given, upon being initially diagnosed with prostate cancer, for each of the following aspects? - Explanation of your treatment options

11

GfK HealthCare

Which information sources did patients find most useful following diagnosis?

76%

14%

7%

76%

20%

4%

58%

8%

30%

76%

22%

82%

10%

88%

10%

2%

The Specialist(Urologist/ Oncologist/ Radiologist/ Other

specialist doctor)

Your GP/ Primary Care Physician

Websites Total France Germany Italy Spain Poland


=52)


Q: Following your initial diagnosis of prostate cancer, which ONE of the following sources of information did you find most useful?

What is important to prostate cancer patients when making decisions about their treatment

options?

13

GfK HealthCare

How do patients prefer treatment decisions to be made?

2%

40%

58%

18%

82%

2%

2%

18%

78%

56%

44%

8%

56%

36%

50%

50%

Prefer to discuss your treatment options with yourdoctor and decide on the best treatment option

together

Prefer your doctor to decide what works best

Prefer to be given the name of an alternative physicianfor a second opinion

Prefer several physicians in consultation to decidewhat works best

Don't know



=52)


Q: Which ONE of the following options best describes how you would prefer your doctor to approach treatment decisions with you?

14

GfK HealthCare

How informed do patients feel about their treatment options?

2%

1%

12%

35%

50%

2%

2%

18%

78%

2%

16%

22%

60%

2%

10%

62%

26%

2%

6%

8%

26%

58%

4%

21%

44%

31%

Well informed, with theopportunity to discuss the

available options

Well informed, but hadlittle or no say with regard

to the available options

Poorly informed, with littleor no choice with regard tothe treatment programme

I trust my doctor

Yet to discuss thetreatment options

Don't know



=52)


Q: With regard to the treatment options you were given, which one of the following options best describes how informed you felt?

15

GfK HealthCare

What other factors are important to patients when making treatment decisions?


=52)


Importance ranking 1st - 4th Side-effectsImpact on

your lifestyle

Impact on your partner /

familyCost of the treatment

Ranked first 42% 40% 14% 4%

Ranked second 32% 35% 28% 6%

Ranked third 25% 19% 45% 11%

Ranked forth 1% 6% 13% 80%

Mean 1.9 1.9 2.6 3.7

Standard deviation 0.8 0.9 0.9 0.7

Standard error 0.05 0.06 0.06 0.05

Q: Aside from the effectiveness of your treatment, please rank, in order of their importance to you, the following factors that you feel your doctor should take into account when making treatment decisions.

16

GfK HealthCare

If impact on lifestyle is important to patients, have they discussed this with their physician?

2%

28%

70%

25%

75%

40%

60%

11%

89%

6%

25%

69%

5%

40%

55%

Yes

No

Don't know


Base: All respondents who ranked 'impact on your lifestyle' as the most important factor in their treatment decision

(Total=102/France=8/Germany=30/Italy=28/Spain=16/Poland=20)


Q: Having ranked 'impact on lifestyle' as the most important consideration your physician should take into account (aside from the effectiveness of the treatment), have you discussed this with him/her?

17

GfK HealthCare

Why haven’t some patients discussed impact on lifestyle with their physician?

Base: All respondents who ranked 'impact on your lifestyle' as the most important factor in their treatment decision but did not discuss this with their physician (Total=31/France=2/Germany=12/Italy=3/Spain=5/Poland=9)


61%

23%

16%

10%

50%

0%

50%

42%

8%

25%

25%

100%

67%

60%

40%

20%

78%

22%

You didn't thinkabout it at the time

You didn't feel itwould make any

difference if it wasmentioned or not

You didn't have achance to speak toanyone about thetreatment options

It is personal /private


Q: What has held you back from discussing the potential impact your treatment may have on your lifestyle?

18

GfK HealthCare

What is most important to prostate cancer patients following diagnosis?


=52)


Importance ranking 1st - 4th Controlling my

disease

Maintaining as much of a

normal lifestyle as possible

Minimising the impact of my disease

on my family

Having as few visits to

the doctor for treatment as

possible

Ranked first 65% 27% 6% 2%

Ranked second 24% 53% 19% 4%

Ranked third 9% 17% 59% 15%

Ranked forth 2% 3% 15% 80%

Mean 1.5 2 2.8 3.7

Standard deviation 0.7 0.8 0.8 0.6

Standard error 0.05 0.05 0.05 0.04

Q: Having been diagnosed with prostate cancer, please rank, in order of their importance to you, the following four options.

silent voice survey a survey of prostate cancer patients in europe overview of results

Documents